<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress.com" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
	xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
	>
<url><loc>https://fdawatch.net/2026/07/20/fda-legal-regulatory-compliance-issues-part-1-fda-doj-enforcement/</loc><news:news><news:publication><news:name>FDA Watch Podcast</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-20T12:15:19+00:00</news:publication_date><news:title>FDA Legal, Regulatory &#038; Compliance Issues, Part 1: FDA &#038; DOJ Enforcement</news:title><news:keywords>FDA, regulation, FDA Watch, pharmaceuticals, technology, News, food, art, compliance, enforcement, pharma, sports, regulatory policy, litigation, GLP-1, DOJ, Department of Justice, Alibaba, Gabriel Scannapieco, AGG, Arnall Golden Gregoy, resolution, life sciences, legal</news:keywords></news:news><image:image><image:loc>https://fdawatch.net/wp-content/uploads/2025/08/fdawatch_artworkupdated8.5.jpg?w=150</image:loc></image:image></url></urlset>